Kodiak debuts IPO
Palo Alto, California-based Kodiak Sciences Inc, a biopharmaceutical company focused on treating chronic, high-prevalence retinal diseases, has debuted its IPO after pricing its 9 million shares at $10 per share. The stock began trading October 4, 2014 on the NASDAQ under the ticker symbol "KOD." Morgan Stanley and BofA Merrill Lynch are the lead underwriters. Kodiak's pre-IPO backers include ArrowMark Partners and Perceptive Advisors, according to Crunchbase.
4 October 2018•2 mins read
